FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer. PMID 40781051 · Urol Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): 3-year follow-up of a randomised, controlled trial. PMID 40780241 · Lancet Rheumatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials. PMID 40779895 · Cancer Treat Rev · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Letter to the Editor: Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open‑label, phase II/III study. PMID 40768025 · Gastric Cancer · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ultrasound-Guided Stellate Ganglion Block Regulates Inflammatory Cytokines and Improves Short-Term Outcome after Cardiac Surgery with Cardiopulmonary Bypass: A Randomized Clinical Trial. PMID 40764224 · J Cardiothorac Vasc Anesth · 2025-Nov The study is a randomized trial in cardiac surgery, not oncology. It evaluates an intervention (stellate ganglion block) for inflammatory cytokines and short-term outcomes after cardiac surgery. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and does not meet the oncology or efficacy endpoint criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial. PMID 40759832 · Breast Cancer Res Treat · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic ovarian drilling vs. step-up gonadotropin therapy in infertile anovulatory polycystic ovary syndrome women resistant to sequential letrozole and gonadotropin-based ovulation induction cycles: a randomized controlled trial. PMID 40759374 · F S Sci · 2025-Nov 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy. PMID 40750720 · Am J Cardiovasc Drugs · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide. PMID 40742002 · BJU Int · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results. PMID 40738833 · Clin Lung Cancer · 2025-Nov The study is a Phase IIIb trial in oncology (ES-SCLC) with human subjects, a drug-containing intervention, and time-to-event efficacy endpoints (OS, PFS). However, it is explicitly described as a 'single-arm study' in the methods, which does not meet the requirement for randomization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies. PMID 40730715 · CNS Drugs · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study. PMID 40711960 · J Urol · 2025-Nov The trial is oncology-related, involves human patients with prostate cancer, is randomized, phase 3, includes a drug intervention (metformin), and reports original results. However, it is excluded because the primary efficacy endpoint is not a time-to-event outcome; it is a cross-sectional proportion at a fixed time point. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dietary Fiber Intake and Prostate Cancer Outcomes and All-Cause Mortality: Findings From a Secondary Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Study. PMID 40684909 · J Acad Nutr Diet · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial. PMID 40683357 · J Am Acad Dermatol · 2025-Nov The trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, the primary efficacy endpoint is treatment failure at 24 months (a binary outcome), not a time-to-event endpoint with survival analysis. No Kaplan-Meier curves, hazard ratios, or time-to-event data are reported. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data. PMID 40680994 · Ann Oncol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931. PMID 40680992 · Ann Oncol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials. PMID 40650860 · Patient · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial. PMID 40639387 · Lancet Infect Dis · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy. PMID 40637120 · Eur J Heart Fail · 2025-Nov The study meets oncology, human, randomized, drug intervention, and original result criteria. However, it lacks a required time-to-event efficacy endpoint; the primary outcome is a binary categorical measure (CTRCD incidence) at 12 months, not a survival or time-to-event analysis. Therefore, it is excluded from the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. PMID 40582920 · Clin Lung Cancer · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial. PMID 40576049 · Amyotroph Lateral Scler Frontotemporal Degener · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC. PMID 40545237 · J Thorac Oncol · 2025-Nov 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Indirect Comparison of Maralixibat and Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis. PMID 40544071 · Clin Ther · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Treatment Effect Estimation With Potential Outcomes for a Single-Arm Trial Compared With Historical Controls: A Case Study of Locally Recurrent Head and Neck Squamous Cell Carcinoma Patients Treated With Adjuvant Nivolumab. PMID 40525328 · Head Neck · 2025-Nov The record describes a single-arm trial analyzed with historical controls, not a randomized trial. It also appears to be a methodological study comparing statistical techniques rather than a primary report of a randomized Phase II/III or III trial with a drug intervention and time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial. PMID 40509748 · Arthritis Rheumatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Hospitalizations as an outcome measure in COURAGE-ALS. PMID 40503807 · Amyotroph Lateral Scler Frontotemporal Degener · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer. PMID 40485075 · J Clin Pharmacol · 2025-Nov The study is an original report of a phase III randomized trial in oncology with a drug intervention, but it presents a cardiac safety analysis (QT prolongation) and does not report on a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the required time-to-event criterion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer. PMID 40473034 · J Hepatol · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study. PMID 40455066 · Eur J Heart Fail · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN-Open-Label Study. PMID 40439027 · Mov Disord Clin Pract · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Restoring TADS: RIAT reanalysis of the Treatment for Adolescents with Depression Study. PMID 40421808 · Int J Risk Saf Med · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST. PMID 40418277 · Int J Hematol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia. PMID 40413154 · Clin Lymphoma Myeloma Leuk · 2025-Nov The report is a safety analysis of cardiac events from three Phase 3 randomized trials. It does not report a primary or key secondary time-to-event efficacy endpoint required for inclusion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. PMID 40381735 · J Hepatol · 2025-Nov 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: five-year results from a randomized phase II trial. PMID 40380996 · Surg Today · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration. PMID 40349982 · Ophthalmol Retina · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. PMID 40338282 · Clin Transl Oncol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of the cyclosporine in Takotsubo syndrome (CIT) trial. PMID 40268179 · Am Heart J · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): A Randomized Controlled Trial. PMID 40180292 · Gastroenterology · 2025-Nov The study is an oncology-related randomized trial with time-to-event endpoints and original results, but it does not meet the drug-intervention requirement, which is mandatory for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study. PMID 39954913 · Clin Gastroenterol Hepatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study. PMID 39694205 · Clin Gastroenterol Hepatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial. PMID 39174409 · Eur Urol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial. PMID 40474841 · Br J Surg · 2025-May-31 The study is a randomized phase III trial in oncology with drug interventions, but the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or HR). The efficacy endpoints mentioned are TIL-IMP manufacture failure rates and response rates (objective response), which are categorical outcomes, not time-to-event endpoints. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| WITHDRAWN: Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial. PMID 40451669 · Dig Liver Dis · 2025-May-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy of Shaomazhijing granules in the treatment of Tourette's syndrome: a randomized controlled trial. PMID 40450353 · Hereditas · 2025-May-31 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Design of a Patient-Centered Hierarchal Composite Outcome for a Multi-Center Randomized Controlled Trial in Metastatic Bone Disease. PMID 40558261 · Curr Oncol · 2025-May-30 The record describes the design and outcome development for a randomized controlled trial (PERFORM), but it does not report the results of a completed Phase III or Phase II/III trial. The primary outcomes identified are composite and include mortality, physical function, and days at home, but there are no results reported for these endpoints (no KM curves, HRs, etc.). The study is explicitly a protocol/design paper for an ongoing trial, not an original result report. Furthermore, the intervention is surgical (reconstruction vs. fixation), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). PMID 40448185 · Trials · 2025-May-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. PMID 40447307 · BMJ · 2025-May-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The efficacy of combined lateral and anterior quadratus lumborum blocks in postoperative pain management following pelvic tumor resection: a randomized controlled trial. PMID 40442734 · J Orthop Surg Res · 2025-May-29 The study is a randomized controlled trial in oncology patients (pelvic tumor resection) but it is not a drug-containing intervention trial for a systemic oncology therapy. The intervention is a regional anesthetic nerve block (Quadratus lumborum block) for postoperative pain management. There is no specified trial phase (Phase III/IIIb or Phase II/III), and the primary endpoints are postoperative pain scores, opioid consumption, and recovery quality—none of which are the required time-to-event efficacy endpoints (OS, PFS, etc.) with Kaplan-Meier or HR analysis for an oncology drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials. PMID 40442612 · BMC Gastroenterol · 2025-May-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |